FIELD: biotechnology.
SUBSTANCE: invention relates to fusion proteins based on polypeptides specifically binding to the human complement component C5, and can be used in medicine for the treatment of a patient with a complement component C5-mediated disorder. Fusion proteins are proposed that include an engineered polypeptide containing a VHH domain that specifically binds to the human complement component C5, and an engineered polypeptide containing a VHH domain that specifically binds to human serum albumin, fused directly or through a linker.
EFFECT: invention provides for the production of a fusion protein comprising engineered polypeptides that specifically bind to human complement component C5 and serum albumin, respectively, without reducing the binding of serum albumin to FcRn or without reducing the half-life of serum albumin.
22 cl, 12 dwg, 20 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
| MOLECULES TARGETING A TYPE III SECRETION SYSTEM | 2016 |
|
RU2759949C2 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
